Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 7 of 7 results for faricimab

  1. Faricimab for treating diabetic macular oedema (TA799)

    Evidence-based recommendations on faricimab (Vabysmo) for diabetic macular oedema in adults.

    Technology appraisal guidance
    Published
    29 June 2022
    View recommendations

    Sections for TA799

  2. Faricimab for treating wet age-related macular degeneration (TA800)

    Evidence-based recommendations on faricimab (Vabysmo) for wet age-related macular degeneration in adults.

    Technology appraisal guidance
    Published
    29 June 2022
    View recommendations

    Sections for TA800

  3. Faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion [ID6197]

    In development [GID-TA11148] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Bevacizumab gamma for treating wet age-related macular degeneration [ID6320]

    In development [GID-TA11193] Expected publication date: 11 December 2024

    Technology appraisal guidance
    In development

  5. Brolucizumab for treating diabetic macular oedema (TA820)

    Evidence-based recommendations on brolucizumab (Beovu) for diabetic macular oedema in adults.

    Technology appraisal guidance
    Published
    31 August 2022
    View recommendations

    Sections for TA820

  6. Supporting the health and care system in improving productivity

    Recovering core services and improving productivity is an immediate priority for the NHS. To help, we’ve put all our relevant guidance and recommendations supporting this work in one place.

  7. NICE welcomes life sciences review recommendations

    NICE’s priority is to get the best care to patients fast while ensuring value for the taxpayer.

    News
    Last updated
    22 January 2024